These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38358597)

  • 21. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; Konopleva M; Pemmaraju N
    Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting CD123 in BPDCN: an emerging field.
    DiPippo AJ; Wilson NR; Pemmaraju N
    Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients.
    Pemmaraju N; Cuglievan B; Lasky J; Kheradpour A; Hijiya N; Stein AS; Meshinchi S; Mullen CA; Angelucci E; Vinti L; Mughal TI; Pawlowska AB
    EJHaem; 2024 Feb; 5(1):61-69. PubMed ID: 38406504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
    Egger A; Coello D; Kirsner RS; Brehm JE
    J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
    Togami K; Pastika T; Stephansky J; Ghandi M; Christie AL; Jones KL; Johnson CA; Lindsay RW; Brooks CL; Letai A; Craig JW; Pozdnyakova O; Weinstock DM; Montero J; Aster JC; Johannessen CM; Lane AA
    J Clin Invest; 2019 Nov; 129(11):5005-5019. PubMed ID: 31437130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm - collected cases from a single center and case reports.
    Faustmann P; Schroeder JC; Mix L; Harland L; Riedel A; Vogel W; Lengerke C; Wirths S
    Front Oncol; 2024; 14():1384172. PubMed ID: 38665943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report.
    Sibai J; Chen R; Nabhani IA; Perusini MA; Sibai H
    EJHaem; 2022 Nov; 3(4):1374-1376. PubMed ID: 36467820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
    Adimora IJ; Wilson NR; Pemmaraju N
    Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
    Abla D; Abboud MR; Noun D; Tarek N; Pemmaraju N
    Leuk Res Rep; 2022; 17():100313. PubMed ID: 35462725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
    Economides MP; Rizzieri D; Pemmaraju N
    Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Hammond D; Pemmaraju N
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):565-574. PubMed ID: 32336420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
    Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN
    Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495
    [No Abstract]   [Full Text] [Related]  

  • 33. A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients.
    Gong C; Liu Y; Zhang M
    Ther Adv Hematol; 2024; 15():20406207241251602. PubMed ID: 38832237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
    Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blast and Bursts: Unveiling Splenic Rupture in Blastic Plasmacytoid Dendritic Cell Neoplasia.
    Hassan A; Simpson M; Jiwani R; Arrigo A; Nisarga P; Esan OA; Koget A
    J Community Hosp Intern Med Perspect; 2024; 14(5):96-100. PubMed ID: 39399205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venetoclax and Azacitidine in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory to Conventional Therapy.
    Azad F; Zhang J; Miranda CJ; Gravina M
    Cureus; 2022 Dec; 14(12):e33109. PubMed ID: 36726910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.
    Wu SJ; Sadigh S; Lane AA; Pinkus GS
    Am J Clin Pathol; 2023 May; 159(5):455-463. PubMed ID: 36880313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
    Pemmaraju N; Kantarjian H; Sweet K; Wang E; Senapati J; Wilson NR; Konopleva M; Frankel AE; Gupta V; Mesa R; Ulrickson M; Gorak E; Bhatia S; Budak-Alpdogan T; Mason J; Garcia-Romero MT; Lopez-Santiago N; Cesarman-Maus G; Vachhani P; Lee S; Bhatt VR; Blum W; Walter RB; Bixby D; Gojo I; Duvic M; Rampal RK; de Lima M; Foran J; Fathi AT; Hall AC; Jacoby MA; Lancet J; Mannis G; Stein AS; Mims A; Rizzieri D; Olin R; Perl A; Schiller G; Shami P; Stone RM; Strickland S; Wieduwilt MJ; Daver N; Ravandi F; Vasu S; Guzman M; Roboz GJ; Khoury J; Qazilbash M; Aung PP; Cuglievan B; Madanat Y; Kharfan-Dabaja MA; Pawlowska A; Taylor J; Tallman M; Dhakal P; Lane AA
    Blood; 2023 Feb; 141(6):567-578. PubMed ID: 36399715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
    Zhang X; Sun J; Yang M; Wang L; Jin J
    Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
    Cheng W; Yu TT; Tang AP; He Young K; Yu L
    Curr Med Sci; 2021 Jun; 41(3):405-419. PubMed ID: 34218354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.